Another study performing targeted scDNA-seq in CLL patients showed that the use of single-targeting agents, such as BTK inhibitors and BCL2 inhibitors, could give rise to a state of mutual exclusivity among resistance-associated genes in subclones of CLL patients [119]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.